Measuring the number of immune T-cells in urine could be used to help identify kidney damage in people with ANCA-associated vasculitis (AAV), a new study suggests. These urinary T-cells also may aid in predicting treatment responses and the risk of future disease relapse. “Their promising potential as noninvasive…
Higher blood levels of the molecule pro-calcitonin (PCT) are a marker of lung infection among ANCA-associated vasculitis (AAV) patients with lung disease, a new study reports. Combining PCT with other blood markers can further increase the accuracy of identifying infection, and may be useful for distinguishing between AAV-related lung…
Over the past year, ANCA Vasculitis News has brought you coverage of the latest developments in research related to ANCA-associated vasculitis (AAV). We look forward to continuing to bring you news about advances in research and treatment in the new year. Here we have compiled a list of the top…
Hepatitis E infection can be effectively managed in people with ANCA-associated vasculitis (AAV) by pausing immunosuppressive therapy, though patients may experience AAV flares during this pause, a new study shows. “Despite potent immunosuppression before infection, all patients cleared the virus after cessation of the immunosuppressant without additional anti-viral therapy.
People with ANCA-associated vasculitis (AAV) are at an increased risk of experiencing cardiovascular problems, such as a stroke, according to a new study done in South Korea. Indeed, AAV patients were found to have a more than two times higher risk of cardiovascular health problems than individuals without any…
Two cases of teen boys with ANCA-associated vasculitis (AAV) that caused heart problems — a very rare manifestation of the autoimmune disease — were described in a recent report. AAV-related heart issues may contribute to serious health concerns such as stroke, so it is important to screen for these…
After approximately $3.7 billion in acquisitions, Amgen will own the rights to Tavneos (avacopan), an approved oral therapy developed by ChemoCentryx to treat ANCA-associated vasculitis (AAV). Amgen is acquiring ChemoCentryx in a cash deal, expected to be completed by year’s end, the companies announced. “The acquisition of ChemoCentryx represents a…
Measuring the blood levels of a protein called BAFF could help predict the chances of remission after induction treatment with rituximab in people with ANCA vasculitis (AAV), according to a new study. Determining the BAFF levels in the blood also could guide further care for AAV patients, the researchers…
Levels of five small RNA molecules were found to be highly elevated in extracellular vesicles — small packets of cellular cargo — found in the urine of people with ANCA-associated vasculitis (AAV), a new study reports. These preliminary findings indicate the impairment of these RNA molecules might be linked…
Health Canada has approved the oral medicine Tavneos (avacopan) as an add-on therapy to treat adults with severe ANCA-associated vasculitis (AAV). The approval specifically covers the use of Tavneos to treat granulomatosis polyangiitis (GPA) and microscopic polyangiitis (MPA), the two main types of AAV, in combination with…
Get regular updates to your inbox.